AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04746313 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood test
Description: * to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin
Study NCT04481945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bioceramic sealer
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
Study NCT04481945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioceramic sealer
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
Study NCT02866461 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: Observation
Study NCT05298228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam bolus does administration
Description: The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
Study NCT05628987 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention
Study NCT05236764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
Study NCT06594796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)
Description: One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
Study NCT06586216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Experimental
Study NCT06592833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin, 25mg, given once orally.
Study NCT06592833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin, 25mg, given once orally.
Study NCT06592833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimavanserin
Description: Pimavanserin, 34mg, given once orally
Study NCT06592833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study NCT04592211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib+pembrolizumab+paclitaxel
Description: olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly
Study NCT06657378 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06659341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3498264
Description: Oral
Study NCT06661122 — intervention group
Intervention type: DRUG
Intervention: Darolutamide (BAY1841788) + docetaxel + ADT
Description: Follow clinical practice/administration. ADT=androgen deprivation therapy.
Study NCT06655142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCObind (Onco-Seraph) 100 Filter
Description: The ONCObind Microbind® Affinity Blood Filter ( ONCObind) manufactured by ExThera Medical Corporation in Martinez, CA. The ONCObind filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. Literature search yielded over 60 publications and 500 treated patients with Seraph platform technology for pathogen removals without and significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of ONCObind consistent with the intended use. ExThera Medical concludes that the known and potential benefits of ONCObind, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
Study NCT06655142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Matched Controls
Description: Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
Study NCT05472818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]APP311
Description: For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
Study NCT06601686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (TES)
Description: TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
Study NCT06601686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation with temporal interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
Study NCT06601686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current.
Study NCT03555968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0
Description: THC dose = 0mg
Study NCT03555968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC 0
Description: THC dose = 0mg
Study NCT03555968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg
Study NCT03555968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 10
Description: THC dose = 10mg
Study NCT03555968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAC 0
Description: Blood alcohol concentration = .000%
Study NCT03555968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC 0
Description: Blood alcohol concentration = .000%
Study NCT03555968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .025
Description: Blood alcohol concentration = .025%
Study NCT03555968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .049
Description: Blood alcohol concentration = .049%
Study NCT06315686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
Study NCT06037512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: subject
Description: blood glucose measurement by subject
Study NCT06037512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: reference
Description: blood glucose measurement with reference
Study NCT04737759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Care of Us
Description: A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
Study NCT04737759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SUPPORT
Description: SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
Study NCT04630210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day oral until surgery
Study NCT04630210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery
Study NCT06609083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 30mg
Description: High dose of THC (30 mg)
Study NCT06609083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5mg
Description: Low dose of THC (5 mg)
Study NCT06609083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0mg
Description: Placebo dose of THC (0 mg)
Study NCT06609083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Full Nicotine
Description: Full nicotine cigarette
Study NCT06609083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Reduced Nicotine
Description: Reduced nicotine cigarette
Study NCT06609538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives standard preoperative instructions and propofol or ketamine infusion.
Study NCT06609538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suggestion Group
Description: Receives positive preoperative suggestions and propofol or ketamine infusion.
Study NCT05344612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Coronary Angiography
Description: Upfront ct-coronary angiography
Study NCT06168474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified layered consent form
Description: The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.
Study NCT06168474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-length consent form
Description: The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
Study NCT05427175 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Patients will receive 8 sessions of NB-UVB per month for 3 successive months
Study NCT06669754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant
Description: Deucrictibant 40mg extended-release tablet for once daily oral use
Study NCT06669754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05939336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mannooligosaccharides yeast extract
Description: 15 g per day of mannooligosaccharide yeast extract.
Study NCT05427175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study NCT05374434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional irrigation
Description: The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
Study NCT05374434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial cavitation
Description: The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
Study NCT06506786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden-fresh Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
Study NCT06506786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supermarket Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
Study NCT05496062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Toffee Nasal and Toffee Nasal Pillows Masks
Description: F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
Study NCT05998902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trophic enteral feeding combined with supplemental parenteral nutrition
Description: The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.
Study NCT05998902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full enteral feeding
Description: The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
Study NCT06379412 — intervention group
Intervention type: OTHER
Intervention: observational study, no intervention
Description: observational study, no intervention
Study NCT05251974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quest beta blocker assay
Description: Blood assay to detect presence of beta blocker medications
Study NCT06284174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution; chlorhexidine gluconate
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
Study NCT06284174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Povidone-iodine solution; chlorhexidine gluconate
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
Study NCT04336111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrolaminar block
Description: will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
Study NCT05320120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 56mg esketamine (2x Spravato® 28 mg nasal spray)
Description: 56mg esketamine (2x Spravato® 28 mg nasal spray)
Study NCT05320120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution nasal spray
Description: 0.9% saline solution nasal spray
Study NCT05109156 — intervention group
Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study NCT06060782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
Description: All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days
Study NCT05238090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive and active analytical stretching exercises
Description: For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process.
Study NCT05238090 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
Description: Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
Study NCT05255536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block with 20 ml
Description: Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
Study NCT05255536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block with 30 ml
Description: Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
Study NCT05494333 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: NO intervention
Study NCT06021535 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05428410 — intervention group
Intervention type: OTHER
Intervention: IL-4R
Description: IL-4R was injected subcutaneously.
Study NCT05440084 — intervention group
Intervention type: PROCEDURE
Intervention: Chronic total occlusion percutaneous coronary intervention
Description: Chronic total occlusion percutaneous coronary intervention
Study NCT05572658 — intervention group
Intervention type: BIOLOGICAL
Intervention: mRNA-1345
Description: Sterile liquid for injection
Study NCT05572658 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT06541704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Subcutaneous (SC) injection
Study NCT06541704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC injection
Study NCT05080504 — intervention group
Intervention type: DEVICE
Intervention: Eko DUO
Description: Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days.
Study NCT05428410 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Placebo was injected subcutaneously.
Study NCT05436717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDxYOU
Description: The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
Study NCT06139029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% normal saline
Description: nebulization
Study NCT06139029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline
Description: nebulization